Durbin Expanded Access Program Resources Center
As Expanded Access Program (EAP) experts, we keep our finger on the pulse of a fast-moving environment. We have created this space as a touchstone through which you can keep up to date with the very latest expanded access activity and insights.
Durbin Expanded Access Program Resources Center
As Expanded Access Program (EAP) experts, we keep our finger on the pulse of a fast-moving environment. We have created this space as a touchstone through which you can keep up to date with the very latest expanded access activity and insights.
Scroll Down
Solving Surprising Expanded Access Program Supply Chain Challenges
A pharmaceutical company contracted Durbin’s Expanded Access experts in 2018 for a unique
product.
product.
Evaluating the Cost Impact of an Expanded Access Program
The ultimate goal of an EAP is to provide much-needed treatment to patients who have an urgent need, but companies must find balance in managing program costs.
Implementing Real World Data Collection in Expanded Access Programs (EAPs)
Building Real-World Data collection initiatives into an EAP design can offer apparent benefits. What are some of the considerations and practical implementation solutions for RWD collection in expanded access?
Optimizing Commercial Launch for Orphan Drugs With Expanded Access Programs
There are between 25 and 30 million people in the U.S. alone living with rare conditions. EAPs can be instrumental in both ensuring patient access to treatment, and as a key step on the path to commercialization
The Expanded Access Program (EAP) Playbook
When considering running an expanded access program (EAP), drug manufacturers typically find themselves at a crossroad, weighing up the benefits of delivery against the obstacles that might be in the way.
COVID-19 Is No Obstacle to Expanded Access
COVID-19 is no obstacle to expanded accessCOVID-19 is no obstacle to expanded access
Global Early Access Program for New Medicine
Durbin appointed by Jazz Pharmaceuticals to Coordinate Global Early Access Program for New Medicine
